Illinois
CNS clinical trials in Illinois
140 CNS studies are recruiting participants at sites in 60 cities across Illinois as of November 16, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Every Illinois city with a recruiting study
By research area: Depression (52), Parkinson's Disease (22), Schizophrenia (22), Multiple Sclerosis (20), Epilepsy (11), Migraine (8), Bipolar Disorder (3), ADHD (2).
Chicago (110), Naperville (11), Evanston (8), Springfield (6), Skokie (5), Warrenville (5), Urbana (4), Champaign (3), Arlington Heights (2), Carterville (2), Flossmoor (2), Hines (2), Oak Brook (2), Oak Lawn (2), Orland Park (2), Peoria (2), Aurora (1), Barrington (1), Bloomington (1), Canton (1), Carthage (1), Crystal Lake (1), Danville (1), Decatur (1), DeKalb (1), Dixon (1), Downers Grove (1), Effingham (1), Elgin (1), Elmhurst (1), Eureka (1), Galesburg (1), Geneva (1), Glenview (1), Grayslake (1), Gurnee (1), Harvey (1), Hazel Crest (1), Highland Park (1), Hoffman Estates (1), Kewanee (1), Lake Forest (1), Libertyville (1), Lisle (1), Macomb (1), Mattoon (1), Maywood (1), Mount Vernon (1), Normal (1), Northbrook (1), O'Fallon (1), Oak Park (1), Ottawa (1), Park Ridge (1), Pekin (1), Peru (1), Plainfield (1), Princeton (1), Rockford (1), Washington (1).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Depression: recently updated in Illinois
Basic details from each study's public record (the 12 most recently updated of 140). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Recruiting in
- Warrenville
- Registry record
- NCT07226661 · updated
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Phase 3
- Ages 18 to 85
- All sexes
- Sponsor
- Cybin IRL Limited
- Recruiting in
- Chicago
- Registry record
- NCT06793397 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Illinois on ClinicalTrials.gov.
Schizophrenia: recently updated in Illinois
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Phase 3
- Ages 13 to 17
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Recruiting in
- Chicago
- Registry record
- NCT07288567 · updated
Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Illinois on ClinicalTrials.gov.
ADHD: recently updated in Illinois
The Myelin Disorders Biorepository Project
- Observational
- All ages
- All sexes
- Sponsor
- Children's Hospital of Philadelphia
- Recruiting in
- Chicago
- Registry record
- NCT03047369 · updated
Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Illinois on ClinicalTrials.gov.
Parkinson's disease: recently updated in Illinois
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- AstraZeneca
- Recruiting in
- Arlington Heights · Evanston
- Registry record
- NCT06989112 · updated
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- Boston Scientific Corporation
- Recruiting in
- Chicago
- Registry record
- NCT02071134 · updated
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Skokie
- Registry record
- NCT06345729 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Chicago
- Registry record
- NCT06841354 · updated
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Chicago
- Registry record
- NCT06952504 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Illinois on ClinicalTrials.gov.
Epilepsy: recently updated in Illinois
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Rapport Therapeutics Inc.
- Recruiting in
- Springfield
- Registry record
- NCT07563881 · updated
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Rapport Therapeutics Inc.
- Recruiting in
- Chicago
- Registry record
- NCT07594119 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Illinois on ClinicalTrials.gov.
Migraine: recently updated in Illinois
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Recruiting in
- Gurnee · Skokie
- Registry record
- NCT07816367 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Illinois on ClinicalTrials.gov.
Ask about studies in Illinois
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections